Actual Medicinal Product (AMP) Aromasin 25mg tablets (Pfizer Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
Medicines suitable for use in MCAs, although use is likely to be off-label. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
- Notes
-
No special precautions for storage.
- Provenance
-
This compatibility recommendation is derived from Aromasin 25mg tablets (Pfizer Ltd).
- Generic
- Exemestane
- Formulation
- Exemestane 25mg tablets
-
Exemestane
-
Exemestane 25mg tablets
-
Aromasin 25mg tablets (Pfizer Ltd)
-
-